TY - JOUR
TI - In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
AU - Papakonstantinou, V.D.
AU - Chini, M.
AU - Mangafas, N.
AU - Stamatakis, G.M.
AU - Tsogas, N.
AU - Tsoupras, A.B.
AU - Psarra, K.
AU - Fragopoulou, E.
AU - Antonopoulou, S.
AU - Gargalianos, P.
AU - Demopoulos, C.A.
AU - Lazanas, M.-C.
JO - Lipids in Health and Disease
PY - 2014
VL - 13
TODO - 1
SP - null
PB - BioMed Central Ltd.
SN - 1476-511X
TODO - 10.1186/1476-511X-13-90
TODO - 1 alkyl 2 acetylglycerophosphocholine esterase;  abacavir;  antiretrovirus agent;  efavirenz;  emtricitabine;  high density lipoprotein;  interleukin 10;  interleukin 12p70;  interleukin 1beta;  interleukin 6;  interleukin 8;  lamivudine;  low density lipoprotein;  tenofovir;  thrombocyte activating factor;  tumor necrosis factor alpha;  vasculotropin;  adenine;  anti human immunodeficiency virus agent;  benzoxazine derivative;  efavirenz;  interleukin 10;  interleukin 6;  interleukin 8;  lamivudine;  phosphonic acid derivative;  tenofovir;  thrombocyte activating factor;  tumor necrosis factor alpha, adult;  article;  cardiovascular risk;  cholesterol blood level;  clinical article;  enzyme activity;  enzyme linked immunosorbent assay;  human;  Human immunodeficiency virus infection;  in vivo study;  leukocyte;  male;  thrombocyte;  analogs and derivatives;  animal;  HIV Infections;  metabolism;  middle aged, Human immunodeficiency virus, Adenine;  Adult;  Animals;  Anti-HIV Agents;  Benzoxazines;  HIV Infections;  Humans;  Interleukin-10;  Interleukin-6;  Interleukin-8;  Lamivudine;  Male;  Middle Aged;  Organophosphonates;  Platelet Activating Factor;  Tumor Necrosis Factor-alpha
TODO - Background: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients. Methods. Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/ efavirenz (Group-T) or abacavir/lamivudine/efavirenz (Group-A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures. Results: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen. Conclusions: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration. © 2014 Papakonstantinou et al.; licensee BioMed Central Ltd.
ER -